Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Sanofi patents new YAP1/TEAD interaction inhibitors

Nov. 3, 2021

Targeting IRE1-mediated ER stress response and lipid reshuffling for reprogramming TME

Nov. 3, 2021

iTeos Belgium describes new ENT1 inhibitors

Nov. 2, 2021

Mitobridge discloses new CD38 inhibitors

Nov. 2, 2021

Almirall patents new TYK2 inhibitors

Nov. 2, 2021

FD-223, a novel PI3Kdelta inhibitor with potent activity in models of AML

Nov. 2, 2021

Single-cell atlas of SCLC tumors identifies plasticity, metastasis, and immunosuppression signatures

Oct. 29, 2021

Agios Pharmaceuticals, University of Michigan present menin/MLL interaction inhibitors

Oct. 29, 2021

New ENPP1 inhibitors discovered at Betta Pharmaceuticals

Oct. 28, 2021

Medshine Discovery presents new DNA-dependent protein kinase inhibitors

Oct. 28, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.